Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yanwen Diao
Institution:
Liaoning Cancer Hospital & Institute
Observed institution:
Liaoning Cancer Hospital & Institute
ORCID:
0000-0003-2109-2285
Observed ORCID:
0000-0003-2109-2285
OpenAlex ID:
A5083322455
Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
2022
·
Qian Dong
, Yanwen Diao
, et al.
·
BMJ Open
·
10
PDF
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature
2024
·
Haobo Yin
, Yanwen Diao
, et al.
·
Immunotherapy
·
6
PDF
Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case
2026
·
Yanwen Diao
, Haobo Yin
, et al.
·
Frontiers in Immunology
·
1
PDF
Abstract 6002: Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter, phase II trial (TRAP)
2025
·
Jingdong Zhang
, Qian Dong
, et al.
·
Cancer Research
·
1
Sequential combination treatment with TKIs and anti-PD-1 therapy in TKI-responsive patients with metastatic MSS/pMMR colorectal cancer: an open-label, single-arm phase 2 trial
2026
·
Jingdong Zhang
, Qian Dong
, et al.
·
Research Square
PDF
A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-H
2025
·
Yanwen Diao
, Yang Zhou
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
6
Citation count:
18
H-index:
2
I10-index:
1
Year
Topic
Type